Resources Repository
-
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Costing Methods | Government/Law | Health/Medicine | Preferences/Values | Benefit-Cost Analysis | Chronic Disease/Risk | Mental Health | Policy/Regulation | Economics/Finance | North America -
ReportPublication 2018Estimating the Distributional Impact of Increasing Taxes on Tobacco Products in Armenia
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors …
Smoking is considered the leading risk factor for mortality among the Armenian population. The authors conducted an extended cost-effectiveness analysis (ECEA) on increases in the excise tax on cigarettes in Armenia. Based on the World Health Organization recommendations, they analyzed the impact of a 75% increase of excise tax on the retail price of cigarettes. The ECEA found large health and financial benefits to the excise tax. It averted about 88,000 premature deaths, US$63 million of OOP…
Cost-Effectiveness Analysis | Government/Law | Health/Medicine | Priority Setting/Ethics | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Economics/Finance | Europe -
ReportPublication 2015Returns on HTA Funded Research
This report from the RAND Corporation dissects the impact of the Health Technology Assessment (HTA) …
This report from the RAND Corporation dissects the impact of the Health Technology Assessment (HTA) program in making quality research accessible and cost-effective. The authors conduct an economic analysis to illustrate benefits of new interventions in two ways: through improved health, measured in QALYs, and through showing that the intervention allows for the same health outcome and a lower cost. The report utilizes economic analyses and case studies to make recommendations. These recommendations include considering…
Costing Methods | Health Outcomes | Health/Medicine | Evidence Synthesis | Health Systems | Economics/Finance | Science/Technology | Europe -
ReportPublication 2015Modeling to Improve Policy Decisions in the Americas: Noncommunicable Diseases
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only …
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only to human health, but also to a country’s economic development and growth. The evidence on both of these counts is compelling. In 2012, cardiovascular disease, diabetes, cancers, chronic respiratory conditions including asthma, and other NCDs were the cause of 4.5 million deaths in the Americas. Of that total number, 1.5 million of them were premature, occurring among people aged 30-69…
Cost-Effectiveness Analysis | Costing Methods | Health/Medicine | Priority Setting/Ethics | Mathematical Models | State-Transition | Microsimulation | Decision Analysis | Chronic Disease/Risk | Mental Health | Latin America & Caribbean -
ReportPublication 2023Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health
This ISPOR Task Force report examines the integration of patient preferences into healthcare decision-making, emphasizing …
This ISPOR Task Force report examines the integration of patient preferences into healthcare decision-making, emphasizing the growing significance of both qualitative and quantitative methods for studying these preferences. The report synthesizes current best practices to enhance the utility and impact of patient-preference studies. The methods involved reviewing existing literature and practices to construct the ISPOR Roadmap for Patient Preferences in Decision Making. This roadmap encourages collaboration among researchers, decision-makers, patients, patient groups, and other stakeholders.…
Health Outcomes | Health/Medicine | Preferences/Values | Evidence Synthesis -
ReportPublication 2022Investment Case for New Tuberculosis Vaccines
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will …
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will save lives, fight antimicrobial resistance, advance health equity, improve economic growth, and bring a substantial return on investment. This World Health Organization (WHO) report describes the full value proposition for new TB vaccines. These analyses articulate the broader economic impacts of new TB vaccines to guide global stakeholders when making investment decisions for novel TB vaccines and to plan for…
Cost-Effectiveness Analysis | Health/Medicine | Infectious Diseases | Economics/Finance | Global -
ReportPublication 2022Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
The article introduces the CHEERS 2022 statement, an updated set of guidelines for reporting health …
The article introduces the CHEERS 2022 statement, an updated set of guidelines for reporting health economic evaluations. Health economic evaluations compare alternative actions in terms of costs and consequences. The original CHEERS statement, published in 2013, aimed to make these evaluations clear, interpretable, and useful for decision-making by providing a standardized reporting format. Methods involved reviewing advancements in health economic evaluation methods and the need for inclusive stakeholder engagement, including patients and the public. The…
Cost-Effectiveness Analysis | Health/Medicine -
ReportPublication 2019Top 10 Health Economics and Outcomes Research Trends
As governments and other payers struggle with provision of the best possible health outcomes at …
As governments and other payers struggle with provision of the best possible health outcomes at affordable costs, the field of health economics and outcomes research (HEOR) has experienced rapid growth. The International Society for Pharmacoeconomics Outcomes Research (ISPOR) produced the ISPOR 2019 Top 10 HEOR Trends which serves to outline the top 10 that the Society members identified that will be the most impactful during 2019. Development of this report included a comprehensive review and…
Health Outcomes | Health/Medicine | Social Determinants | Health Systems | Policy/Regulation | Global Governance | Science/Technology | Global -
ReportPublication 2018Understanding the Economics of Microbial Threats: Proceedings of a Workshop
This report follows a June 2018, Forum on Microbial Threats that was held at the …
This report follows a June 2018, Forum on Microbial Threats that was held at the National Academies of Sciences, Engineering, and Medicine. This was a 1.5-day public workshop with the goal being an assessment of the current understanding of the interaction of infectious disease threats and economic activity in order to suggest future areas of research. This workshop built on prior work of the Forum and aimed to build more mutual understanding between those in…
Health Outcomes | Health/Medicine | Evidence Synthesis | Technology Assessment | Infectious Diseases | Policy/Regulation | Global Governance | Clinical Care | Business/Industry | Economics/Finance | Global